The effect of carvedilol on morbidity and mortality in patients with chronic heart failure

New England Journal of Medicine

Volumn 334, Issue 21, 1996, Pages 1349-1355

  Packer, Milton ^a   Bristow, Michael R ^b   Cohn, Jay N ^c   Colucci, Wilson S ^d   Fowler, Michael B ^e   Gilbert, Edward M ^f   Shusterman, Neil H ^g  

^a The New York Presbyterian Hospital   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^d BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^g GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ADULT; ARTICLE; CAUSE OF DEATH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY RISK; DOUBLE BLIND PROCEDURE; DYSPNEA; FATIGUE; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MORTALITY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; VERTIGO;

ADRENERGIC ALPHA-ANTAGONISTS; ADRENERGIC BETA-ANTAGONISTS; CARBAZOLES; CARDIOVASCULAR DISEASES; CHRONIC DISEASE; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; FEMALE; FREE RADICAL SCAVENGERS; HEART FAILURE, CONGESTIVE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; PROPANOLAMINES; RISK;

EID: 0029937949     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199605233342101     Document Type: Article

References (40)

1. Thomas JA, Marks BH. Plasma norepinephrine in congestive heart failure. Am J Cardiol 1978;41:233-43.
2. Cohn JN, Levine TB, Olivari MT, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984;311:819-23.
3. Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol 1992;20:248-54.
4. Bristow MR. Pathophysiologic and pharmacologic rationales for clinical management of chronic heart failure with beta-blocking agents. Am J Cardiol 1993;71:12C-22C.
5. Yates JC, Beamish RE, Dhalla NS. Ventricular dysfunction and necrosis produced by adrenochrome metabolite of epinephrine: relation to pathogenesis of catecholamine cardiomyopathy. Am Heart J 1981;102:210-21.
6. Mann DL, Kent RL, Parsons B, Cooper G IV. Adrenergic effects on the biology of the adult mammalian cardiocyte. Circulation 1992;85:790-804.
7. ver Donck L, Wouters L, Olbrich HG, Mutschler E, Borgers M. Nebivolol increases survival in cardiomyopathic hamsters with congestive heart failure. J Cardiovasc Pharmacol 1991;18:1-3.
8. Sabbah HN, Shimoyama H, Kono T, et al. Effects of long-term monotherapy with enalapril, metoprolol, and digoxin on the progression of left ventricular dysfunction and dilation in dogs with reduced ejection fraction. Circulation 1994;89:2852-9.
9. Epstein SE, Braunwald E. The effect of beta adrenergic blockade on patterns of urinary sodium excretion: studies in normal subjects and in patients with heart disease. Ann Intern Med 1966;65:20-7.
10. Waagstein F, Hjalmarson A, Varnauskas E, Wallentin I. Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J 1975;37:1022-36.
11. Swedberg K, Hjalmarson A, Waagstein F, Wallentin I. Prolongation of survival in congestive cardiomyopathy by beta-receptor blockade. Lancet 1979;1:1374-6.
12. Eichhorn EJ, Heesch CM, Barnett JH, et al. Effect of metoprolol on myocardial function and energetics in patients with nonischemic dilated cardiomyopathy: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 1994;24:1310-20.
13. Fisher ML, Gottlieb SS, Plotnick GD, et al. Beneficial effects of metoprolol in heart failure associated with coronary artery disease: a randomized trial. J Am Coll Cardiol 1994;23:943-50.
14. Woodley SL, Gilbert EM, Anderson JL, et al. Beta-blockade with bucindolol in heart failure caused by ischemic versus idiopathic dilated cardiomyopathy. Circulation 1991;84:2426-41.
15. Bristow MR, O'Connell JB, Gilbert EM, et al. Dose-response of chronic β-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy. Circulation 1994;89:1632-42.
16. Olsen SL, Gilbert EM, Renlund DG, Taylor DO, Yanowitz FD, Bristow MR. Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study. J Am Coll Cardiol 1995;25:1225-31.
17. Metra M, Nardi M, Giubbini R, Cas LD. Effects of short- and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 1994;24:1678-87.
18. Krum H, Sackner-Bernstein JD, Goldsmith RL, et al. Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure. Circulation 1995;92:1499-506.
19. Waagstein F, Bristow MR, Swedberg K, et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet 1993;342:1441-6.
20. CIBIS Investigators and Committees. A randomized trial of β-blockade in heart failure: the Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 1994;90:1765-73.
21. Bril A, Slivjak M, DiMartino MJ, et al. Cardioprotective effects of carvedilol, a novel beta adrenoceptor antagonist with vasodilating properties, in anaesthetized minipigs: comparison with propranolol. Cardiovasc Res 1992;26:518-25.
22. Ruffolo RR Jr, Gellai M, Heible JP, Willette RN, Nicholas AJ. The pharmacology of carvedilol. Eur J Clin Pharmacol 1990;38:Suppl 2:S82-S88.
23. Yoshikawa T, Port JD, Asano K, et al. Cardiac adrenergic effects of carvedilol. Eur Heart J (in press).
24. Yue T-L, Cheng H-Y, Lysko PG, et al. Carvedilol, a new vasodilator and beta adrenoceptor antagonist, is an antioxidant and free radical scavenger. J Pharmacol Exp Ther 1992;263:92-8.
25. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
26. Cox DR. Regression models and life-tables. J R Stat Soc [B] 1972;34:187-202.
27. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics 1979;35:549-56.
28. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. Br J Cancer 1976;34:585-612.
29. Gilbert EM, Olsen SL, Renlund DG, Bristow MR. Beta-adrenergic receptor regulation and left ventricular function in idiopathic dilated cardiomyopathy. Am J Cardiol 1993;71:23C-29C.
30. 1 vs nonselective β-blockade in human congestive heart failure: acute effects on cardiac sympathetic activity. Circulation 1995;92:Suppl I:I-395. abstract.
31. Bristow MR, Olsen S, Gilbert EM, et al. β-blockade with carvedilol selectively lowers cardiac adrenergic drive in lhe failing human heart. J Am Coll Cardiol 1992;19:146A. abstract.
32. Dhalla AK, Singh N, Singal PK. Antioxidant therapy associated with the reversal of oxidative stress delays the pathogenesis of heart failure. Circulation 1994;90:1-491. abstract.
33. Sackner-Bernstein J, Krum H, Goldsmith RL, et al. Should worsening heart failure early after initiation of beta-blocker therapy for chronic heart failure preclude long-term treatment? Circulation 1995;92:Suppl I:I-395. abstract.
34. Waagstein F, Caidahl K, Wallentin I, Bergh CH, Hjalmarson A. Long-term β-blockade in dilated cardiomyopathy: effects of short- and long-term metoprolol treatment followed by withdrawal and readministration of metoprolol. Circulation 1989;80:551-63.
35. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
36. Packer M, Rouleau J, Swedberg K, et al. Effect of flosequinan on survival in chronic heart failure: preliminary results of the PROFILE Study. Circulation 1993;88:Suppl I:I-301. abstract.
37. Feldman AM, Bristow MR, Parmley WW, et al. Effects of vesnarinone on morbidity and mortality in patients with heart failure. N Engl J Med 1993; 329:149-55.
38. Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure: results of a Veterans Administration Cooperative Study. N Engl J Med 1986;314:1547-52.
39. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316: 1429-35.
40. Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med 1991;325:1468-75.